Unlock full details of this profile with our free Lite plan!
Sign Up and Get Free AccessPhase Genomics - About the company
Phase Genomics is a series A company based in Seattle (United States), founded in 2015 by Ivan Liachko and Shawn Sullivan. It operates as a Provider of laboratory and computational services and products. Phase Genomics has raised $5.75M in funding. The company has 220 active competitors, including 57 funded and 26 that have exited. Its top competitors include companies like Tessera Therapeutics, Candel Therapeutics and Genedit.
Company Details
Provider of laboratory and computational services and products. The company has developed technology that allows the extraction of information regarding the physical proximity of DNA stretches inside the nucleus from short- or long-read HT sequencing allowing researchers to reconstruct the 3D organization of DNA within the nucleus. Phase Genomics' Proximo Hi-C measures the proximity of DNA in vivo and uses that information to scaffold contigs into entire chromosomes, or to deconvolute metagenomes from complex mixtures of environmental DNA.
- Website
- phasegenomics.com
- Social
- Email ID
- *****@phasegenomics.com
Key Metrics
Founded Year
2015
Location
Seattle, United States
Stage
Series A
Total Funding
$5.75M in 19 rounds
Latest Funding Round
Investors
Ranked
3rd among 220 active competitors
Employee Count
19 as on Dec 31, 2021
Similar Companies
Legal entities associated with Phase Genomics
Phase Genomics is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Dec 31, 2014 | - | 19 (as on Dec 31, 2021) | - |
Get your free copy of Phase Genomics's company profile
Phase Genomics's funding and investors
Filter this listPhase Genomics has raised a total funding of $5.75M over 19 rounds. Its first funding round was on Jun 12, 2016. Its latest funding round was a Grant (prize money) round on Mar 05, 2024 for $1.5M. 1 investor participated in its latest round, which include Catapult, Congruent Ventures, Sahsen Ventures and NIAID.
Phase Genomics has 13 institutional investors including Catapult, Congruent Ventures and Sahsen Ventures.
Here is the list of recent funding rounds of Phase Genomics:
Date of funding | Funding Amount | Round Name | Post money valuation | Revenue multiple | Investors |
|---|---|---|---|---|---|
Mar 05, 2024 | $1.5M | Grant (prize money) | 1331244 | 3545879 | |
Sep 25, 2023 | $2M | Grant (prize money) | 8532631 | 4322667 | |
Aug 07, 2023 | $2.5M | Grant (prize money) | 7979063 | 6195651 |
Access funding benchmarks and valuations. Sign up today!View details of Phase Genomics's funding rounds and investors
Phase Genomics' founders and board of directors
Founder? Claim ProfileThe founders of Phase Genomics are Ivan Liachko and Shawn Sullivan.
Here are the details of Phase Genomics' key team members:
- Ivan Liachko: Co-Founder of Phase Genomics. Contact Info: 1 email address
- Shawn Sullivan: Co-Founder of Phase Genomics. Contact Info: 1 email address
View details of Phase Genomics's Founder profiles and Board Members
Phase Genomics' employee count trend
Phase Genomics has 19 employees as of Dec 21. The total employee count is 27.0% more than what it was in Dec 20. Here is Phase Genomics's employee count trend over the years:Uncover Phase Genomics' growth story! Sign up today!Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Phase Genomics's Competitors and alternates
Top competitors of Phase Genomics include Tessera Therapeutics, Candel Therapeutics and Genedit. Here is the list of Top 10 competitors of Phase Genomics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Overall Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Tessera Therapeutics 2017, Cambridge (United States), Series C | Provider of new genome engineering technology for treating multiple diseases | $610M | 64/100 | |
2nd | Candel Therapeutics 1999, Needham (United States), Public | Developer of viral immunotherapies for the treatment of cancer | $65.2M | 60/100 | |
3rd | Phase Genomics 2015, Seattle (United States), Series A | Provider of laboratory and computational services and products | $5.75M | 58/100 | |
4th | Genedit 2016, Berkeley (United States), Series B | Developer of drug delivery system for genetic medicines | $93.5M | 58/100 | |
5th | Genenta Science 2014, Milan (Italy), Public | Developer of lentivirus-based gene and cell therapies for cancer | $33.6M | 57/100 | |
6th | Developing delivery system of proteins inside cells directly | $40.4M | 56/100 | ||
7th | PreventionGenetics 2004, Marshfield (United States), Acquired | Provider of sequencing services and duplication tests for clinical genes | - | - | 55/100 |
8th | CellFE 2018, Berkeley (United States), Series A | Developer of intracellular gene delivery platform | $26.8M | 54/100 | |
9th | Portal 2023, Watertown (United States), Seed | Provider of cell engineering and cell analytics across research and clinical applications | $16.7M | 53/100 | |
10th | LogicBio 2013, Lexington (United States), Acquired | Developer of viral vectors for the treatment of genetic and infectious diseases | $49M | 52/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Phase Genomics's competitors? Click here to see the top ones
Phase Genomics's Investments and acquisitions
Phase Genomics has made no investments or acquisitions yet.
Reports related to Phase Genomics
Here is the latest report on Phase Genomics's sector:
News related to Phase Genomics
Filter this listMedia has covered Phase Genomics for a total of 3 events in the last 1 year, 2 of them have been about people movement.
•
Phase Secures $13 Million to Take on Figma with Advanced UI/UX Design Platformbnext.com.tw•Feb 14, 2025•Phase Genomics, Gobi Partners, 500 Global, 42 Capital and 6 others
•
•
Phase Genomics Announces Appointment of David Shoultz as First Chief Business OfficerBusiness Wire•Oct 09, 2024•Phase Genomics
•
Phase Genomics Announces Funding to Accelerate Discovery of New Lysin-Based Precision AntimicrobialsBioSpace•Mar 05, 2024•Phase Genomics, Gates Foundation
•
Phase Genomics Advances Breakthrough Cytogenomics with the Element AVITI System for Acute Myeloid LeukemiaBusiness Wire•Nov 17, 2023•Phase Genomics
•
•
Phase Genomics Lands $2.5M in Grants to Develop Diagnostic Score For Genomic Aberrations in CancerGenomeWeb•Aug 08, 2023•Phase Genomics
•
Phase Genomics Collaborates with Element Biosciences to Optimize Cytogenomics for Liquid and Solid Tumor SamplesBusiness Wire•Apr 14, 2023•Phase Genomics, Element Biosciences
•
Phase Genomics has filed a notice of an exempt offering of securities to raise $6,579,358.00 in New Equity and Debt Financing.intelligence360•Apr 03, 2023•Phase Genomics, SEC
•
With New Funding, Phase Genomics Seeks to Eliminate One of Biology’s Biggest Blind SpotsBusiness Wire•Jun 10, 2022•Phase Genomics, Gates Foundation, NIAID
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQ's about Phase Genomics
Explore our recently published companies
- Topfootball.in - Mumbai based, 2024 founded, Unfunded company
- Srbagroup - Unfunded company
- Kevis - Hyderabad based, 2016 founded, Unfunded company
- Location Media Xchange - Singapore based, 2020 founded, Unfunded company
- Flipshop Pro - 2024 founded, Unfunded company
- Zenevista - Lagos based, 2024 founded, Unfunded company